Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07396909 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Single and Multiple Ascending Dose Study of MT-701
A Phase 1 study of Healthy Volunteers, sponsored by Mirador Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
- 1
- Study location
NCT07396909: Recruiting Phase 1 study of Healthy Volunteers, sponsored by Mirador Therapeutics.
NCT07396909 is a Phase 1 study of Healthy Volunteers that is actively recruiting participants, run by Mirador Therapeutics. The registered enrollment target is 78 participants, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07396909, a Phase 1 study of Healthy Volunteers, is actively recruiting participants, sponsored by Mirador Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
- 1
- Study location
Study Summary
First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-701 in healthy participants.
Primary Outcome
Incidence of adverse events, clinically significant laboratory abnormalities, clinically significant electrocardiogram, vital signs, and physical examination abnormalities.
Conditions Studied
Interventions
- DRUG MT-701
Study Locations (1)
California
- Mirador Clinical Department - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2026-01-12 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 1 |
What NCT07396909 shows while recruiting
NCT07396909 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which MT-701 is the first listed.
NCT07396909 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07396909 about?
NCT07396909 is a clinical study titled "A First-in-Human Single and Multiple Ascending Dose Study of MT-701". First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-701 in healthy participants.
What is the current status of trial NCT07396909?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2026-01-12. Estimated completion is 2026-10-01.
What conditions does trial NCT07396909 study?
This clinical trial studies the following conditions: Healthy Volunteers.
What interventions are being tested in trial NCT07396909?
The interventions under investigation include: MT-701 (DRUG).
Who is sponsoring clinical trial NCT07396909?
This trial is sponsored by Mirador Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07396909 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07396909's enrollment target sits among peer trials
78 89th of 283 higher than 195 of 283 other Healthy Volunteers trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Volunteers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
RECRUITING · Phase 1
-
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants
RECRUITING · Phase 1
-
A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.
RECRUITING · Phase 1
-
Classroom Break, Cognition, and Fitness in Elementary School Children
RECRUITING · Phase 1
-
A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI